Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest ...
A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American ...
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...
Ascendis Pharma A/S (ASND) said that it has priced its underwritten public offering of 2 million American Depositary Shares or 'ADSs' ...
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American ...
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...
Ascendis Pharma shares are under pressure due to revenue miss, but has growth potential for strong demand for Skytrofa and ...
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...
An earnings miss and sharply reduced guidance for its ONE commercialized product doomed Ascendis Pharma (NASDAQ: ASND) to a ...